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Introduction
Inflammatory myofibroblastic tumour, also known as inflam-
matory fibrosarcoma, plasma cell granuloma, inflammatory
pseudotumour and inflammatory fibroid polyp, is a rare solid
tumour mimicking a malignant neoplasm that grows to a
large size.1,2 With an unknown aetiology, this clinical and
pathological disease entity has been reported in various ana-
tomical sites.3 Though most commonly found in the lung and
mediastinum, intra-abdominal involvement including the liver,
pancreas, stomach, omentum, retroperitoneum and pelvis has
been reported in numerous series.4,5 The tumour is composed
of a dominant spindle-cell (myofibroblast) proliferation
with a variable inflammatory background. Inflammatory
myofibroblastic tumour is a distinctive pseudosarcomatous
lesion that occurs primarily in children and young adults.6 It
usually follows a benign clinical course.
We report a case of intra-abdominal inflammatory
myofibroblastic tumour in a 10-year-old girl with extensive
involvement of the transverse colon, greater omentum, ab-
dominal wall, mesosigmoid and dome of the urinary bladder,
Paediatric Intra-abdominal Inflammatory
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which was mistaken as a left ovarian tumour preoperatively.
The clinical course and pathological features of this unusual
disease are described and discussed.
Case report
A 10-year-old girl suffered from intermittent vague lower
abdominal pain for 2 months. She experienced a variable
degree of constitutional symptoms such as diarrhoea, nausea
and vomiting without bowel habit changes. There was a his-
tory of body weight loss of 6 kg during this period, but no
episode of blunt abdominal trauma or intra-abdominal sepsis
was noted. After seeking help from several medical facilities
in vain, she was brought to our gynaecological outpatient de-
partment for diagnosis and treatment. There was no fever nor
dehydration, and her general appearance was fair.
On physical examination, the abdomen was soft but mildly
distended with increased bowel sounds. There was a palpable
lower abdominal mass about 5 cm in diameter just above the
suprapubic area. Transabdominal sonography showed a large
tumour mass, measuring 6.6 = 6.3 = 4.9 cm, over the left lower
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placed the left kidney, pancreas, stomach and spleen superi-
orly and laterally. There was no obvious regional lymph
node enlargement. The anterior surface of the tumour was
firmly attached to the parietal peritoneum and could not be
demarcated without partial excision of the parietal perito-
neum. We performed debulking for the main mass, partial
omentectomy, excision of the involved abdominal wall and
incidental appendectomy. Intraoperative frozen section and
pathology confirmed an inflammatory myofibroblastic tu-
mour (Figure 3).
The postoperative course was uneventful and the patient
was discharged on the 9th postoperative day. Lower gastro-
intestinal series and abdominal computed tomography
confirmed no recurrence of the lesion 2 and 3 months post-
operatively. There was no recurrence of the tumour or any
disturbing gastrointestinal symptoms during the 15-month
follow-up period.
Discussion
Inflammatory myofibroblastic tumour is an uncommon clini-
cal and pathological disease entity which cannot be distin-
guished from other malignant neoplasms clinically due to its
somewhat malignant behaviour: aggressive local growth and
recurrence after complete resection. Alternative nomenclatures,
such as inflammatory fibrosarcoma, plasma cell granuloma,
inflammatory pseudotumour, inflammatory fibroid polyp and
pseudosarcomatous myofibroblastic proliferation, have been
used to describe various histopathological features of the
same lesion.1,2 The tumour is more common in women and
may affect all organ systems.1
quadrant (Figure 1). The lesion was suggestive of a left
ovarian malignant neoplasm due to the large, fast-growing
size and constitutional symptoms. Several tumour markers
(`-human chorionic gonadotrophin, carcinoembryonic
antigen, _-fetoprotein, CA-125) were within normal limits.
Laboratory evaluation revealed a normal haematogram. Bio-
chemistry and urinalysis were both normal.
Under the impression of left ovarian tumour with sus-
pected malignancy, exploratory laparotomy was performed.
The operative findings included an ill-defined, huge, intra-
abdominal, inflammatory mass, joining the urachus just be-
neath the lower abdominal incision. The mass was rubbery,
glistening and somewhat oedematous in nature with shaggy
margins and fibrous adhesion to the anterior surface of the
transverse colon, anterior abdominal wall, mesosigmoid
and the dome of the urinary bladder, and involving the left
two-thirds of the greater omentum (Figure 2). The mass dis-
Figure 1. Abdominal sonography reveals a left lower quadrant mass
mimicking a left ovarian malignant neoplasm.
Figure 2. The specimen consists of an inflammatory mass in the
greater omentum.
Figure 3. Microscopically, the tumour is composed of spindle cells
arranged in a storiform growth pattern in a myxoid or hyalinized
background with scattered inflammatory cells (haematoxylin &
eosin; original magnification = 200).
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Inflammatory myofibroblastic tumour is composed of
a dominant-spindle cell (myofibroblast) proliferation with
inflammatory polyclonal mononuclear infiltrates (plasma
cells, lymphocytes and histiocytes) in a collagenous, fibrous or
myxoid background. The spindle cells are strongly positive
for vimentin. Smooth-muscle actin, muscle-specific actin and
desmin are positive to a lesser extent.1 Other useful markers
for inflammatory cells include g and h light chains for plasma
cells, CD20 and CD3 for B and T lymphocytes, factor VIII
for endothelial cells and CD68 for histiocytes, with various
degrees of positive staining reported.7,8 Cytokeratin and
S-100 proteins are inconclusive. All of these immunohisto-
chemical studies are contributory when routine haematoxy-
lin-eosin sections alone cannot distinguish inflammatory
myofibroblastic tumours from other sarcomatous lesions or
more malignant neoplasms and a definite diagnosis cannot be
achieved.
Inflammatory myofibroblastic tumours are mostly benign,
but it has been advocated that at least some are true neoplasms,
with the presence of chromosomal abnormalities.9 Anaplas-
tic lymphoma kinase, an oncoprotein typically expressed in
anaplastic large-cell lymphoma, and chromosome rearrange-
ment of 2p23 have been demonstrated in some inflammatory
myofibroblastic tumours, suggesting a clonal proliferation
origin for the disease other than an aberrant inflammatory
response. Treissman et al reported the translocation of [(2,9)
(q1,3;p2,2)] for omental-mesenteric inflammatory pseudo-
tumour with monoclonality in one case.10 Two large series
of extrapulmonary inflammatory myofibroblastic tumour
are summarized in the Table:1,5 the mesentery, omentum and
retroperitoneum are the most commonly involved sites
with high recurrences of 25–37%. Abdominal pain (45%),
fever (37%), mass (42%) and gastrointestinal obstruction (18%)
were dominant symptoms in one series.5
Intra-abdominal involvement of visceral organs and the
mesentery may mimic a soft-tissue mass with invasion or
displacement of surrounding structures on imaging studies.
The clinical presentations of intra-abdominal myofibroblas-
tic tumour include fever of unknown origin, splenomegaly,
abdominal pain, weight loss, bowel obstruction, intussuscep-
tion and other nonspecific symptoms, depending on the
site of the lesion.11 The diagnosis cannot be established pre-
operatively with certainty, even using fine-needle aspiration.
The final diagnosis is confirmed by histopathological fea-
tures after surgical resection.1,12 In the current case, further
immunohistochemical and chromosome studies were not
used since pathology alone was adequate for diagnosis and
additional studies were of no value in predicting disease
recurrence.
Total excision of the tumour is adequate in most circum-
stances, although retroperitoneal and mesenteric inflamma-
tory myofibroblastic tumours seem to be associated with more
frequent recurrence. The disease itself is surgically curable.
Long-term follow-up is needed for potential recurrence even
after complete resection of the tumour. Recurrence is also
managed with surgery and the tendency for recurrence is
related to the lesion site: intra-abdominal tumours seem to be
more aggressive and prone to recurrence than those in other
sites.2 There are no reliable prognostic markers correlating
with local invasiveness, distant metastases and recurrences.13
Adjuvant therapy provides little benefit for inflammatory
myofibroblastic tumour.7
Extensive intra-abdominal myofibroblastic tumour is a
rare lesion and should be recognized when encountered intra-
Table. Demographic features and recurrence of extrapulmonary inflammatory myofibroblastic tumour
Reference Cases Gender (F:M) Age Location Recurrence
Coffin et al1 84 48:36 Mean: 9.7 yr Abdomen, retroperitoneum, pelvis: 61 (73%) 13/53 (25%)
Median: 9 yr Head, neck, upper respiratory tract: 12 (14%)
Range: 3 mo – 46 yr Trunk: 8 (10%)
Extremities: 3 (4%)
Meis & Enzinger5 38 23:15 Mean: 15 yr Mesentery & retroperitoneum: 31 (82%) 10/27 (37%)
Median: 8.5 yr Omentum: 2 (5%)
Range: 2 mo – 74 yr Mediastinum: 2 (5%)
Liver: 1 (3%)
Diaphragm: 1 (3%)
Abdominal wall: 1 (3%)
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operatively. The differential diagnoses include rhabdomyo-
sarcoma, fibrosarcoma, desmoid tumour, malignant fibrous
histiocytoma, Kaposi’s sarcoma and other soft-tissue sarco-
mas.12 There are few mitoses and no cytological atypia for
this naturally benign lesion. However, inflammatory myo-
fibroblastic tumour should be regarded as a potentially malig-
nant lesion characterized by rapid growth, local invasiveness
and recurrence after tumour resection.14,15 The diagnosis of
inflammatory myofibroblastic tumour is established by thor-
ough histopathological examination of the tumour followed
by immunohistochemical analyses if microscopic features are
not conclusive. The difficulties in making a definite diagnosis
preoperatively make total removal of the tumour the best
choice to avoid any further surgery. Life-time follow-up is
certainly needed due to the risk of recurrence. The aetiology of
this disease remains unknown.
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